Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
CiPA advances proarrhythmia risk assessment beyond QT prolongation; leaves open full regulatory integration pending further validation.
Cases of drug-induced QT prolongation and sudden cardiac deaths resulted in market withdrawal of many drugs and world-wide regulatory changes through accepting the ICH guidelines E14 and S7B. However, because the guidelines were not comprehensive enough to cover the electrophysiological changes by drug-induced cardiac ion channel blocking, CiPA was initiated by experts in governments and academia in the USA, Europe, and Japan in 2013. Five years have passed since the launch of the CiPA initiative that aimed to improve the current ICH guidelines. This report reviews the current achievements of the CiPA initiative and explores unresolved issues.
No takes yet. Share an insight, caveat, or question.
Dong‐Seok Yim (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: